Publications by authors named "R Jarvis Brownlie"

Article Synopsis
  • Brain metastases significantly impact patients with metastatic melanoma, with a severe prognosis and limited durable responses to combined immune checkpoint inhibitors like PD-1 and CTLA-4, especially in symptomatic cases.
  • Research shows that natural killer (NK) cells play a crucial role in enhancing the effectiveness of immune therapy against brain tumors, while their depletion leads to poorer outcomes and decreased CD8+ T cell levels within tumors.
  • The study reveals that the effectiveness of PD-1/CTLA-4 blockade is dependent on chemokine-driven trafficking of CD8+ T cells to intracranial tumors, highlighting the complexity of immune responses in the brain.
View Article and Find Full Text PDF

Protein tyrosine phosphatases (PTPs) play central roles in the regulation of cell signaling, organismal development, cellular differentiation and proliferation, and cancer. In the immune system, PTPs regulate the activation, differentiation and effector function of lymphocytes and myeloid cells whilst single-nucleotide polymorphisms (SNPs) in PTP-encoding genes have been identified as risk factors for the development of autoimmunity. In this review we describe the roles for PTP nonreceptor type 22 (PTPN22) in the regulation of T lymphocyte signaling and activation in autoimmunity, infection and cancer.

View Article and Find Full Text PDF

Phosphotyrosine phosphatase non-receptor type 22 (PTPN22) is a key regulator of immune cell activation and responses. Genetic polymorphisms of PTPN22 have been strongly linked with an increased risk of developing autoimmune diseases, while analysis of PTPN22-deficient mouse strains has determined that PTPN22 serves as a negative regulator of T cell antigen receptor signaling. As well as these key roles in maintaining immune tolerance, PTPN22 acts as an intracellular checkpoint for T cell responses to cancer, suggesting that PTPN22 might be a useful target to improve T cell immunotherapies.

View Article and Find Full Text PDF

Background: Adoptive cell therapy (ACT) is a promising strategy for treating cancer, yet it faces several challenges such as lack of long-term protection due to T cell exhaustion induced by chronic TCR stimulation in the tumor microenvironment. One benefit of ACT, however, is that it allows for cellular manipulations, such as deletion of the phosphotyrosine phosphatase non-receptor type 22 (PTPN22), which improves CD8 T cell antitumor efficacy in ACT. We tested whether cytolytic T cells (CTLs) were also more effective than CTL in controlling tumors in scenarios that favor T cell exhaustion.

View Article and Find Full Text PDF